艾塞那肽对早期2型糖尿病肾病患者血糖水平及肾功能的影响

Effect of Exenatide on Blood Glucose Level and Renal Function of Patients with Early Type 2 Diabetic Nephropathy

目的探究艾塞那肽对早期2型糖尿病肾病患者血糖水平及肾功能的影响。方法该研究共选取该院2018年4月—2021年1月收治的93例早期2型糖尿病肾病患者为研究对象,按照随机数表法分为研究组(46例)和对照组(47例)。两组均给予饮食调理、运动锻炼,对照组进行常规口服降糖药联合甘精胰岛素治疗,研究组进行常规口服降糖药联合艾塞那肽治疗,两组治疗周期均为4个月。比较两组治疗前临床指标、治疗前后血糖、肾功能。结果两组治疗前,研究组临床指标BMI、SBP水平分别为(28.62±2.44)kg/m^(2)、(136.07±9.93)mmHg,对照组BMI、SBP水平分别为(28.54±2.39)kg/m^(2)、(134.85±10.80)mmHg,两组数据对比差异无统计学意义(t=0.162、0.567,P>0.05);两组治疗后,研究组的血糖水平FPG(6.32±1.08)mmol/L、2 hPG(8.53±1.26)mmol/L、HbA1c(5.86±0.74)%均低于对照组的(7.89±1.23)、(10.26±1.54)mmol/L、(6.32±0.86)%,差异有统计学意义(t=6.411、5.922、2.762,P<0.05);研究组的肾功能指标Scr(70.10±10.13)μmol/L、CysC(0.67±0.23)mg/L、UACR(49.74±6.62)mg/g均低于对照组的(76.97±17.52)μmol/L、(1.39±0.38)mg/L、(76.96±7.57)mg/g,差异有统计学意义(t=2.308、11.025、18.443,P<0.05)。结论艾塞那肽能有效降低早期2型糖尿病肾病患者血糖水平,保护肾功能,改善病情,延缓肾病进展。

Objective To explore the effect of exenatide on blood glucose levels and renal function of patients with early type 2 diabetic nephropathy.Methods The study selected a total of 93 patients with early type 2 diabetic nephropathy who were admitted to the hospital from April 2018 to January 2021 as the research objects,and were divided into the study group(46 cases)and the control group(47 cases)according to the random number table method.Both groups had diet adjustment,sports exercise.The control group received conventional oral hypoglycemic drugs combined with insulin glargine.The study group was treated with conventional oral hypoglycemic drugs combined with exenatide.The treatment period of both groups was 4 months.The clinical indicators before treatment,blood glucose level,and renal function before and after treatment were compared.Results Before treatment in the two groups,the clinical indicators of BMI and SBP in the study group were(28.62±2.44)kg/m^(2) and(136.07±9.93)mmHg,and the levels of BMI and SBP in the control group were(28.54±2.39)kg/m^(2) and(134.85±10.80)mmHg,there was no statistically significant difference in the data between the two groups(t=0.162,0.567,P>0.05);after treatment in the two groups,the blood glucose level of the study group was(6.32±1.08)mmol/L,2 hPG(8.53±1.26)mmol/L and HbA1c(5.86±0.74)%were lower than those in the control group(7.89±1.23),(10.26±1.54)mmol/L and(6.32±0.86)%,and the differences were statistically significant(t=6.411,5.922,2.762,P<0.05);renal function indexes Scr(70.10±10.13)μmol/L,CysC(0.67±0.23)mg/L,UACR(49.74±6.62)mg/g were all lower in the study group Compared with the control group(76.97±17.52)μmol/L,(1.39±0.38)mg/L,(76.96±7.57)mg/g,the differences were statistically significant(t=2.308,11.025,18.443,P<0.05).Conclusion Exenatide can effectively reduce blood glucose levels in patients with early type 2 diabetic nephropathy,protect renal function,improve the condition,and delay the progression of kidney disease.